Equities research analysts at William Blair have revised their earnings per share (EPS) estimates for Zealand Pharma A/S, raising the forecast for fiscal year 2025 to $13.32. This adjustment, announced on November 13, 2023, reflects an increase from the previous estimate of $13.04. The consensus estimate for the company’s current full-year earnings stands at a negative $2.19 per share. Additionally, William Blair has projected Zealand Pharma’s Q4 2025 earnings at ($1.50) EPS.
Recent Analyst Ratings
The stock has garnered attention from various research firms recently. On July 24, 2023, Wells Fargo & Company upgraded Zealand Pharma to a “strong-buy” rating. Subsequently, Zacks Research elevated its rating from “strong sell” to “hold” on September 15, 2023. Currently, five equity research analysts have assigned a strong buy rating to the stock, while one analyst has issued a hold rating. According to data from MarketBeat.com, Zealand Pharma A/S holds a consensus rating of “Strong Buy.”
As of November 13, 2023, Zealand Pharma’s stock opened at $79.50, reflecting a decline of 1.2%. The company’s fifty-day simple moving average is $73.54, while its two-hundred-day moving average stands at $66.03. Over the past year, the stock has experienced a low of $49.98 and a high of $114.72. The company maintains a market capitalization of $5.65 billion and has a price-to-earnings (PE) ratio of 5.58.
Quarterly Earnings Performance
Zealand Pharma A/S recently reported its quarterly earnings, revealing an EPS of ($0.90) for the quarter, surpassing the consensus estimate of ($1.11) by $0.21. The company achieved a remarkable net margin of 73.90% and a return on equity of 67.06%. Revenue for the quarter reached $7.76 million, significantly exceeding analysts’ expectations of $4.54 million.
Zealand Pharma A/S is a biotechnology company based in Denmark, specializing in the discovery, development, and commercialization of peptide-based medicines. The company’s portfolio addresses gastrointestinal and metabolic diseases, as well as other areas with unmet medical needs. Among its notable products is Dasiglucagon, which is available as a single-use syringe or autoinjector for the treatment of severe hypoglycemia. Additionally, Zealand Pharma has developed Dasiglucagon bi-hormone artificial pancreas systems that combine insulin and dasiglucagon.
Investors and market watchers are keenly observing the developments surrounding Zealand Pharma as it navigates the complex landscape of biotechnology and pharmaceutical innovation.
